The FDA has approved Otarmeni, the first gene therapy for inherited hearing loss caused by mutations in the OTOF gene.
Developed by Regeneron, Otarmeni will be provided free to U.S. patients and is administered via a surgical procedure similar to cochlear implantation.
Clinical trials showed significant hearing improvements in most children treated, marking a major advance for those with this rare form of genetic deafness.
After this breakthrough for a rare gene, how close are we to curing common hearing loss?
Regeneron’s therapy lasts two years so far, but is this a permanent cure for deafness?
Beyond just hearing, can this gene therapy truly replicate the nuances of natural sound perception?
With the drug free but procedure costly, who will truly get this game-changing deafness therapy?
Will this success make gene therapies the standard treatment for all genetic disorders?
How did the FDA approve a gene therapy so quickly based on such small clinical trials?
Otarmeni: FDA’s First Gene Therapy Restores Hearing in 80% of Children with OTOF-Related Deafness
Overview
In January 2026, the FDA approved Otarmeni, the first gene therapy to treat severe hearing loss caused by mutations in the OTOF gene. This approval was accelerated by the National Priority Review Voucher program due to the therapy's potential to transform care for this rare condition. Developed by Regeneron, Otarmeni uses a dual AAV vector system to deliver a functional gene directly into inner ear cells, restoring the critical otoferlin protein. Clinical trials showed that 80% of patients improved their hearing within 24 weeks, with many reaching normal hearing levels. While Regeneron provides the therapy free in the U.S., patients still face surgery-related costs. The success of Otarmeni is driving research into gene therapies for other genetic hearing losses, though ethical and access challenges remain.